AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9802618
Drug: Adjuvant tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant tamoxifen therapy with irradiation
Trial: 28552806
Drug: Anti-Helicobacter pylori
RxNorm normalized name: Anti-Helicobacter pylori IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-Helicobacter pylori concomitant therapy
Trial: 28552806
Drug: Eradication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication therapy without probiotics
Trial: 26596011
Drug: Postaurical injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postaurical injection of methylprednisolone, 40 mg/2 d for 14 d, combined with Ginkgo dipyidamolum and Alprostadil.
Trial: 26596011
Drug: Oral prednisone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisone, 1 mg/kg/d for 3 d, if effective, prolonging for another 2 d, combined with Ginkgo dipyidamolum and Alprostadil.
Trial: 24132980
Drug: Tasteless solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tasteless solution
Trial: 16549954
Drug: Drug group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug group (heparin, abciximab, or thrombolytics)
Trial: 16549954
Drug: No-drug group
RxNorm normalized name: Heparin group antithrombotic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-drug group
Trial: 16549954
Drug: Drug group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug group (collagen plug devices vs. suture-mediated devices)
Trial: 9820297
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant interferon beta‐1a 22 microg
Trial: 9820297
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant interferon beta‐1a 44 microg
Trial: 2665546
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with vincristine, prednisone, L-asparaginase, and rubidomycin (Group B, n = 118)
Trial: 2665546
Drug: Induction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment with vincristine, prednisone, and L-asparaginase (Group A, n = 122)
Trial: 333084
Drug: Tetracycline 250
RxNorm normalized name: tetracycline 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline 250 mg, 6 times per day for 5 days
Trial: 19846007
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (regular therapy only)
Trial: 17509028
Drug: Alosetron 0.5
RxNorm normalized name: alosetron 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alosetron 0.5 mg once daily
Trial: 17509028
Drug: Alosetron 1
RxNorm normalized name: alosetron 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alosetron 1 mg once daily
Trial: 17509028
Drug: Alosetron 0.5
RxNorm normalized name: alosetron 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alosetron 0.5 mg
Trial: 14512295
Drug: Daunorubicin with
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daunorubicin with standard dose of cytarabine
Trial: 14512295
Drug: Idarubicin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin with standard dose of cytarabine
Trial: 14512295
Drug: Mitoxantrone with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone with standard dose of cytarabine
Trial: 11673750
Drug: Rifampin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (600 mg daily for 5 days)
Trial: 2774052
Drug: Occupational Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational Therapy Maternal Role Preparation Program (4 sessions)
Trial: 891483
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg glucagon (G)
Trial: 891483
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg pethidine plus 0.5 mg atropine (PA)
Trial: 28902334
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Bevacizumab and Triamcinolone
Trial: 25185971
Drug: N‐IRI (nimotuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N‐IRI (nimotuzumab 400 mg weekly plus irinotecan 150 mg/m2 biweekly)
Trial: 25185971
Drug: IRI (irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRI (irinotecan 150 mg/m2 biweekly)
Trial: 16713439
Drug: voglibose (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: voglibose (0.9 mg daily)
Trial: 17152785
Drug: Immunosuppressive/anti-inflammatory therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive/anti-inflammatory therapy
Trial: 8556998
Drug: Rocuronium 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.9 mg kg‐1 after 45 s
Trial: 8556998
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg kg‐1 after 45 s
Trial: 8556998
Drug: Rocuronium 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.9 mg kg‐1 after 60 s
Trial: 8556998
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg kg‐1 after 60 s
Trial: 6104255
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with propranolol and prazosin
Trial: 25752357
Drug: 10-day hybrid
RxNorm normalized name: Ricinus hybridus oil
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day hybrid regimen (PACT-10): pantoprazole 40 mg, amoxicillin 1 g, both twice daily for 10 days; plus clarithromycin 500 mg and tinidazole 500 mg, both twice daily for the last 5 days
Trial: 25752357
Drug: 14-day hybrid
RxNorm normalized name: Ricinus hybridus oil
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day hybrid regimen (PACT-14): pantoprazole 40 mg, amoxicillin 1 g, both twice daily for 14 days; plus clarithromycin 500 mg and tinidazole 500 mg, both twice daily for the last 7 days
Trial: 23298898
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral misoprostol and double‐balloon catheter
Trial: 8986678
Drug: Oxidized regenerated
RxNorm normalized name: Collagen/Oxidized Regenerated Cellulose 55%-45% Topical application Dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxidized regenerated cellulose plus heparin (1,000 U/mL)
Trial: 8490772
Drug: Intramuscular dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular dexamethasone injection along with oral placebo treatment (Group B)
Trial: 8490772
Drug: Oral dexamethasone
RxNorm normalized name: dexamethasone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexamethasone by a tapering schedule associated with placebo intramuscular injection (Group C)
Trial: 8490772
Drug: Intramuscular and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular and oral placebos (Group A)
Trial: 8490772
Drug: Intramuscular dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular dexamethasone injection (Group B)
Trial: 8490772
Drug: Oral dexamethasone
RxNorm normalized name: dexamethasone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexamethasone by a tapering schedule (Group C)
Trial: 3814462
Drug: Nimodipine 60
RxNorm normalized name: nimodipine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 60 mg p.o.
Trial: 3814462
Drug: Nimodipine 30
RxNorm normalized name: nimodipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 30 mg s.l.
Trial: 23523158
Drug: Percutaneous transluminal
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous transluminal angioplasty (PTA) in addition to medical therapy
Trial: 23523158
Drug: Delayed PTA
RxNorm normalized name: Achillea ptarmica whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed PTA after 6 months of medical therapy alone
Trial: 20109997
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride 15 mg TID (up to 90 mg/d if needed)
Trial: 20109997
Drug: Oxybutynin hydrochloride
RxNorm normalized name: Oxybutynin hydrochloride
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxybutynin hydrochloride 2.5 mg TID (up to 15 mg/d if needed)
Trial: 16424716
Drug: Novel repeated
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel repeated pulse treatment with methylprednisolone (1 g/day for 3 days) and cyclophosphamide (15 mg/kg/day for 2 days), followed by dexamethasone 20 mg/day until Pao2 was >11.5 kPa, and repeated pulse therapy if Pao2 was <8.64 kPa
Trial: 9578184
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three proton pump inhibitors
Trial: 7865644
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin (75 mg, 300 mg, enteric coated 300 mg)
Trial: 2475678
Drug: Chronic verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic verapamil treatment
Trial: 770079
Drug: Azapropazone 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azapropazone 1200 mg per day before food
Trial: 23548832
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) plus Virtual Reality Exposure Therapy (VRET)
Trial: 23548832
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) plus Exposure in Vivo
Trial: 21741331
Drug: 4g/L of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4g/L of ascites removed (group 1)
Trial: 21741331
Drug: 8g/L of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8g/L of ascites removed (group 2)
Trial: 19201586
Drug: Magnesium citrate
RxNorm normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium citrate 300 mg/day for 5 weeks (group 1)
Trial: 16636211
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss and exercise therapy (6 months of weekly behavioral therapy for weight loss + exercise training 3 times per week)
Trial: 16636211
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss and exercise therapy
Trial: 15499509
Drug: Disease management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease management programme (DMP) based on weekly telephone monitoring by a case manager
Trial: 11092233
Drug: New weight-reducing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New weight-reducing agent based on natural ingredients
Trial: 9091835
Drug: Seaprose S
RxNorm normalized name: S-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seaprose S (30 mg tablets, 90 mg daily for 14 days)
Trial: 9091835
Drug: Serratio-peptidase (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serratio-peptidase (5 mg tablets, 30 mg daily for 14 days)
Trial: 1334101
Drug: Oat bran
RxNorm normalized name: Oat bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat bran (10.3 g beta-glucan/day)
Trial: 25647168
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group received a $110 voucher for smoking cessation pharmacotherapy and were registered to an automated calling system.
Trial: 25647168
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received standard care including smoking cessation advice, a brochure, and a prescription for smoking cessation medication if requested.
Trial: 24029535
Drug: Telephone-administered cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered cognitive-behavioural therapy (telephone CBT)
Trial: 21631542
Drug: gabapentin and
RxNorm normalized name: Gabapentin and mecobalamin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gabapentin and flumazenil combination
Trial: 19483295
Drug: Routine dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine dosage fosinopril (10 mg once daily)
Trial: 19483295
Drug: Middle dosage
RxNorm normalized name: wheat middlings extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle dosage fosinopril (10 mg twice a day)
Trial: 10639191
Drug: Finasteride (5alpha-reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (5alpha-reductase inhibitor) for 6 days to 6 years
Trial: 9253234
Drug: Clinical data
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical data used to build a predictive model based on 21 variables including age, absence of previous similar episodes, weight loss, rectal bleeding, lack of improvement, and presence of a mass on digital rectal examination.
Trial: 31837959
Drug: Alisertib (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib (30 mg orally twice per day on days 8-15) combined with 7+3 induction chemotherapy (continuous infusion of cytarabine 100 mg/m2 per day on days 1-7 and intravenous bolus of idarubicin 12 mg/m2 per day on days 1-3)
Trial: 31837959
Drug: 7+3 induction
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7+3 induction chemotherapy (cytarabine and idarubicin)
Trial: 29735965
Drug: Mild moxibustion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild moxibustion at bilateral Shenshu (BL23) for 15 min daily, for 4 courses (5 days each with 2 days between courses)
Trial: 29735965
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E soft capsules for 28 days
Trial: 28079918
Drug: Lamivudine daily
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine daily oral dose 60-300 mg (3.9-17.6 mg kg-1)
Trial: 28079918
Drug: Lamivudine daily
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine daily oral dose 8-10 mg kg-1 day-1 for children <14 kg
Trial: 18312874
Drug: Radiofrequency treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiofrequency treatment (all generators)
Trial: 10945508
Drug: Cefdinir 100
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefdinir 100 mg BID
Trial: 8973979
Drug: ConA (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ConA (1.25 micrograms/ml, 2.5 micrograms/ml, and 5.0 micrograms/ml)
Trial: 1478135
Drug: Active music
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active music therapy provided every day for 8 weeks
Trial: 1478135
Drug: Antidepressive drugs
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressive drugs (same for both groups)
Trial: 1478135
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (active music therapy + antidepressive drugs)
Trial: 1478135
Drug: Active music
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active music therapy
Trial: 6420374
Drug: 1-2 units
RxNorm normalized name: varicella-zoster immune globulin
DrugBank: Human varicella-zoster immune globulin (DB11621)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-2 units insulin/kg body weight/24 h with feed
Trial: 6420374
Drug: Feed only
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feed only (no insulin)
Trial: 26562292
Drug: Physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice (PC) antiemetic therapy
Trial: 22282552
Drug: Zephyr® EBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zephyr® EBV treatment
Trial: 18331610
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg once daily for 12 weeks
Trial: 15760403
Drug: Doxorubicin chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin chemotherapy (15 mg/m2 biweekly pre-operatively, single dose intra-operatively, total dosage of 300 mg/m2 post-operatively)
Trial: 15760403
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (transplanted only, no chemotherapy)
Trial: 9669632
Drug: Cisapride, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride, 5 mg three times daily (n = 19)
Trial: 2926468
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 5-FU administered 24 hours a day for a protracted time (10 weeks or more)
Trial: 2926468
Drug: Daily bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily bolus dose of 5-FU administered intravenously for five consecutive days and repeated at 5-week intervals
Trial: 26209642
Drug: Control (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (not specified, but implied as the alternative treatment)
Trial: 19139031
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (Diane(35)Diario) - 35 microg ethinyl-estradiol plus 2 mg cyproterone acetate
Trial: 19139031
Drug: Metformin -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin - 850 mg twice daily
Trial: 17713165
Drug: At 24
RxNorm normalized name: FENTANYL 40MCG/ACTUAT 24HR ION SYSTEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At 24 weeks post-treatment
Trial: 15126801
Drug: Medical castration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical castration with a luteinizing hormone releasing hormone analogue
Trial: 8295585
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine therapy
Trial: 29650363
Drug: Chemotherapy (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (3 preoperative cycles and 3 postoperative cycles of intravenous epirubicin, cisplatin or oxaliplatin, and capecitabine)
Trial: 29650363
Drug: Chemoradiotherapy (preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy (preoperative chemotherapy followed by 45 Gy in 25 fractions of radiotherapy combined with capecitabine and cisplatin)
Trial: 28836960
Drug: Five weekly
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five weekly sessions of psychosocial intervention combined with early palliative care (Arm A)
Trial: 28836960
Drug: Standard cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cancer treatment (Arm C)
Trial: 2323085
Drug: Topical antibiotic
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical antibiotic (gentamicin sulphate)
Trial: 2323085
Drug: Topical antiseptic
RxNorm normalized name: BENZALKONIUM CHLORIDE 1.3 mg in 1 mL TOPICAL GEL [Germ Free Topical Antiseptic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antiseptic (aluminium acetate)
Trial: 223950
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid therapy for 5 days
Trial: 223950
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid therapy for 10 days
Trial: 223950
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid therapy for 15 days
Trial: 31626696
Drug: Phentermine HCl
RxNorm normalized name: phentermine HCl
DrugBank: Phentermine (DB00191)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phentermine HCl 60 mg
Trial: 31626696
Drug: Pitolisant 35.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitolisant 35.6 mg
Trial: 31626696
Drug: Pitolisant 213.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitolisant 213.6 mg
Trial: 28277845
Drug: New mometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New mometasone furoate cream
Trial: 28277845
Drug: Positive control
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive control (marketed Elocon cream)